The goal of this proposal is to develop a novel therapeutic strategy for the treatment of multiple myeloma employing checkpoint abrogators such as UCN-01 in combination with inhibitors of the MEK1/2/MAP kinase pathway. It is based upon the recent discovery that exposure of multiple myeloma and other malignant hematopoietic cells to UCN-01 increases activity of p34cdc2(cdk1), an event associated with MAP kinase activation. Furthermore, interruption of the latter process (e.g., by pharmacologic MEK inhibitors such as U0126 or PD184352) results in a dramatic increase in mitochondrial injury, caspase activation, and apoptosis. Significantly, UCN-01/MEK inhibitor-mediated lethality toward myeloma cells is undiminished by conventional or cell adhesion-related drug resistance mechanisms, or by exogenous survival-related cytokines such as IL-6 and IGF-1. Finally, consistent with evidence that neoplastic cells are selectively impaired in checkpoint control, primary CD138+ bone marrow-derived human myeloma cells appear to be significantly more sensitive than their normal counterparts to this novel strategy.
The specific aims of this proposal are a) to elucidate the mechanism(s) by which UCN-01 and MEK inhibitors interact synergistically in myeloma cells, focusing on the functional significance of perturbations in signaling/cell cycle regulatory pathways (e.g., p34cdc2, Raf/MEK/MAP kinase, NFkB, p27KIP1, and cyclin D1; b) to test the hypothesis that the anti-myeloma activity of the UCN-01/MEK inhibitor regimen can be further enhanced by coadministration of proteasome inhibitors, possibly by sparing the cdc25C phosphatase; c) to test the hypothesis that the clinically relevant geldanamycin analog 17-AAG interacts synergistically with UCN-01 in myeloma cells by mimicking the ability of MEK inhibitors to disrupt the cytoprotective MAP kinase cascade; and d) to establish whether these regimens exert selective toxicity toward primary human myeloma cells while sparing their normal hematopoietic counterparts. It is anticipated that information derived from this proposal will serve as a foundation for initiating Phase I trials combining checkpoint abrogators such as UCN-01 with pharmacologic MEK inhibitors in the treatment of multiple myeloma and possibly other hematologic malignancies. Such studies may also provide a paradigm for the development of a novel therapeutic strategy in which inhibitors of cell cycle regulatory and survival signal transduction pathways are rationally combined in the treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA100866-04
Application #
7060918
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Forry, Suzanne L
Project Start
2003-05-01
Project End
2009-04-30
Budget Start
2006-05-08
Budget End
2009-04-30
Support Year
4
Fiscal Year
2006
Total Cost
$243,515
Indirect Cost
Name
Virginia Commonwealth University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Zhou, Liang; Zhang, Yu; Sampath, Deepak et al. (2018) Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer 118:388-397
Wan, Wen; Pei, Xin-Yan; Grant, Steven et al. (2017) Nonlinear response surface in the study of interaction analysis of three combination drugs. Biom J 59:9-24
Fang, Hong-Bin; Chen, Xuerong; Pei, Xin-Yan et al. (2017) Experimental design and statistical analysis for three-drug combination studies. Stat Methods Med Res 26:1261-1280
Zhang, Yu; Zhou, Liang; Leng, Yun et al. (2017) Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget 8:59476-59491
Holkova, Beata; Kmieciak, Maciej; Bose, Prithviraj et al. (2016) Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk Lymphoma 57:635-43
Holkova, Beata; Zingone, Adriana; Kmieciak, Maciej et al. (2016) A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 22:1067-75
Zhou, L; Zhang, Y; Chen, S et al. (2015) A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia 29:807-18
Nguyen, Tri; Hawkins, Elisa; Kolluri, Akhil et al. (2015) Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL? leukemia cells. Leuk Res 39:65-71
Dasmahapatra, Girija; Patel, Hiral; Friedberg, Johnathan et al. (2014) In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Mol Cancer Ther 13:2886-97
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62

Showing the most recent 10 out of 118 publications